Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Therapeutic drug monitoring of small molecule kinase inhibitors in oncology in a real-world cohort study: does age matter?

Crombag MBS, van Doremalen JGC, Janssen JM, Rosing H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR.

Br J Clin Pharmacol. 2018 Dec;84(12):2770-2778. doi: 10.1111/bcp.13725. Epub 2018 Sep 26.

PMID:
30068020
2.

Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.

Lankheet NAG, Desar IME, Mulder SF, Burger DM, Kweekel DM, van Herpen CML, van der Graaf WTA, van Erp NP.

Br J Clin Pharmacol. 2017 Oct;83(10):2195-2204. doi: 10.1111/bcp.13327. Epub 2017 Jul 4.

3.

Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.

Lankheet NA, Knapen LM, Schellens JH, Beijnen JH, Steeghs N, Huitema AD.

Ther Drug Monit. 2014 Jun;36(3):326-34. doi: 10.1097/FTD.0000000000000004.

PMID:
24305627
4.

Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.

Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, Fuhr U, Wolf J, Jaehde U.

Clin Pharmacokinet. 2011 Sep;50(9):551-603. doi: 10.2165/11593320-000000000-00000.

PMID:
21827214
5.

Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry.

Herbrink M, de Vries N, Rosing H, Huitema AD, Nuijen B, Schellens JH, Beijnen JH.

Ther Drug Monit. 2016 Dec;38(6):649-656.

PMID:
27749781
6.

Development and Validation of a Simultaneous Quantification Method of 14 Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS/MS.

Huynh HH, Pressiat C, Sauvageon H, Madelaine I, Maslanka P, Lebbé C, Thieblemont C, Goldwirt L, Mourah S.

Ther Drug Monit. 2017 Feb;39(1):43-54. doi: 10.1097/FTD.0000000000000357.

PMID:
27861317
7.

Effects of 31 FDA approved small-molecule kinase inhibitors on isolated rat liver mitochondria.

Zhang J, Salminen A, Yang X, Luo Y, Wu Q, White M, Greenhaw J, Ren L, Bryant M, Salminen W, Papoian T, Mattes W, Shi Q.

Arch Toxicol. 2017 Aug;91(8):2921-2938. doi: 10.1007/s00204-016-1918-1. Epub 2016 Dec 28.

8.

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.

Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, Wolter P, Hauschild A, Long GV, Nathan P, Ribas A, Flaherty K, Sun P, Legos JJ, McDowell DO, Mookerjee B, Schadendorf D, Robert C.

Lancet Oncol. 2015 Oct;16(13):1389-98. doi: 10.1016/S1470-2045(15)00087-X.

PMID:
26433819
9.

Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanoma.

Rousset M, Dutriaux C, Bosco-Lévy P, Prey S, Pham-Ledard A, Dousset L, Gérard E, Bouchet S, Canal-Raffin M, Titier K, Molimard M.

Clin Chim Acta. 2017 Sep;472:26-29. doi: 10.1016/j.cca.2017.07.012. Epub 2017 Jul 12.

PMID:
28709799
10.
11.

Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients.

Streit F, Binder L, Hafke A, Brandhorst G, Braulke F, Haase D, Armbrust T, Cameron S, Ramadori G, Oellerich M, Walson P.

Ther Drug Monit. 2011 Oct;33(5):632-43. doi: 10.1097/FTD.0b013e3182263ac4.

PMID:
21912334
12.
13.

Current and future roles of targeted therapy and immunotherapy in advanced melanoma.

Olszanski AJ.

J Manag Care Spec Pharm. 2014 Apr;20(4):346-56. Review.

14.

Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients.

Pursche S, Schleyer E, von Bonin M, Ehninger G, Said SM, Prondzinsky R, Illmer T, Wang Y, Hosius C, Nikolova Z, Bornhäuser M, Dresemann G.

Curr Clin Pharmacol. 2008 Sep;3(3):198-203.

15.

Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib.

MacLean E, Mardekian J, Cisar LA, Hoang CJ, Harnett J.

J Manag Care Spec Pharm. 2016 Aug;22(8):979-90. doi: 10.18553/jmcp.2016.22.8.979.

16.

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.

Schadendorf D, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Lesimple T, Plummer R, Schachter J, Dasgupta K, Manson S, Koruth R, Mookerjee B, Kefford R, Dummer R, Kirkwood JM, Long GV.

Lancet Oncol. 2019 May;20(5):701-710. doi: 10.1016/S1470-2045(18)30940-9. Epub 2019 Mar 27.

PMID:
30928620
17.

Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.

Vogelzang NJ, Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N.

J Manag Care Spec Pharm. 2018 Jun;24(6):525-533. doi: 10.18553/jmcp.2018.24.6.525.

18.

Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.

Mir O, Cropet C, Toulmonde M, Cesne AL, Molimard M, Bompas E, Cassier P, Ray-Coquard I, Rios M, Adenis A, Italiano A, Bouché O, Chauzit E, Duffaud F, Bertucci F, Isambert N, Gautier J, Blay JY, Pérol D; PAZOGIST study group of the French Sarcoma Groupe-Groupe d'Etude des Tumeurs Osseuses (GSF-GETO).

Lancet Oncol. 2016 May;17(5):632-41. doi: 10.1016/S1470-2045(16)00075-9. Epub 2016 Apr 5.

PMID:
27068858
19.

Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies.

Wang ZX, Sun J, Howell CE, Zhou QY, He ZX, Yang T, Chew H, Duan W, Zhou ZW, Kanwar JR, Zhou SF.

Fundam Clin Pharmacol. 2014 Oct;28(5):551-82. doi: 10.1111/fcp.12069. Epub 2014 Mar 21.

PMID:
24612223
20.

Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas.

Roskoski R Jr.

Pharmacol Res. 2017 Mar;117:20-31. doi: 10.1016/j.phrs.2016.12.009. Epub 2016 Dec 9. Review.

PMID:
27956260

Supplemental Content

Support Center